Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: Involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 1, 2009, Pages 47-54

  Yang, Kyung H ^a   Choi, Young H ^a   Lee, Unji ^a   Lee, Joo H ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

Enzyme inducers and inhibitors; Furosemide; Pharmacokinetics; Rats

Indexed keywords

3 METHYLCHOLANTHRENE; CIMETIDINE; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; FUROSEMIDE; ISONIAZID; ORPHENADRINE CITRATE; PROADIFEN; QUININE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSECT CELL; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICROSOME; NONHUMAN; RAT;

EID: 58149231201     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.01.0007     Document Type: Article

References (46)

1. Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm 1979; 7: 1-27.
2. Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J Pharmacokinet Biopharm 1989; 17: 1-46.
3. Smith DE et al. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolic-specific assay. Drug Metab Dispos 1980; 8: 337-342.
4. Yakatan GJ et al. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses. Res Commun Chem Pathol Pharmacol 1979; 24: 465-482.
5. Sekikawa H et al. Biliary excretion of furosemide glucuronide in rabbits. Biol Pharm Bull 1995; 18: 447-453.
6. Lee WI et al. Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. Biopharm Drug Dispos 1997; 18: 753-767.
7. Lambert C et al. Effects of phenobarbital and tobacco smoking on furosemide kinetics and dynamics in normal subjects. Clin Pharmacol Ther 1983; 34: 170-175.
8. Correia MA. Appendix B. Rat and human liver cytochrome P450. Substrate and inhibitor specificities and functional markers. In: Oritz de Montellano PR, ed. Cytochrome P450 Structure, Mechanism, and Biochemistry, 2nd edn. New York and London: Plenum Press, 1995: 607-630.
9. Choi YM et al. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J Pharm Sci 1991; 80: 638-642.
10. Chen L-J, Burka LT. Chemical and enzymatic oxidation of furosemide: formation of pyridinium salts. Chem Res Toxicol 2007; 20: 1741-1744.
11. Williams DP et al. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore. J Pharmacol Exp Ther 2007; 322: 1208-1220.
12. Levine M et al. In vivo cimetidine inhibits hepatic CYP2C6 and CYP2C11 but not CYP1A1 in adult male rats. J Pharmacol Exp Ther 1998; 284: 493-499.
13. Ogiso T et al. Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Biol Pharm Bull 1999; 22: 196-199.
14. Tomkins DM et al. Effects of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 1997; 280: 1374-1382.
15. Conney AH. Environmental factors influencing drug metabolism. In: La du BN, Mandel HG, Way EL, eds. Fundamentals of Drug Metabolism and Drug Disposition. Baltimore: Williams & Wilkins Company, 1971: 269.
16. Sinclair JF et al. Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin. Biochem Pharmacol 2000; 59: 445-454.
17. Ryan DE et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 1985; 260: 6385-6393.
18. Murray M et al. Upregulation of cytochromes P450 2B in rat liver by orphenadrine. Br J Pharmacol 2003; 139: 787-796.
19. Williams JF et al. Effect of phenobarbital and 3-methylcholanthrene pretreatment on the plasma half-life and urinary excretion profile of theophylline and its metabolites in rats. Biochem Pharmacol 1979; 28: 2935-2940.
20. Kim SH et al. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinel Biopharm 1993; 21: 1-17.
21. Bae SK et al. Effect of enzyme inducers and inhibitors on the pharmacokinetics of oltipraz in rats. J Pharm Pharmacol 2005; 57: 443-452.
22. Wrighton SA et al. Identification of the cytochrome P-450 induced by macrolide antibiotics in rat livers as the glucocorticoid responsive cytochrome P450. Biochemistry 1985; 24: 2171-2178.
23. Arlotto MP et al. Studies on the pregnenolone-16 alphacarbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyl transferase. Biochem Pharmacol 1987; 36: 3859-3866.
24. Ross PH et al. Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450s. Biochem Pharmacol 1993; 45: 2239-2250.
25. Lee MG et al. Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide. Res Commun Chem Pathol Pharmacol 1981; 34: 17-28.
26. Shim HJ et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
27. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-780.
28. Øie S, Guentert TW. Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J Pharm Sci 1982; 73: 774-780.
29. Prandota J. Pruitt AW. Furosemide binding to human albumin and plasma of nephrotic children. Clin Pharmacol Ther 1975: 17: 159-165.
30. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
31. Kerremans AL et al. Specimen handling and high-performance liquid chromatographic determination of furosemide. J Chromatogr 1982; 229: 129-139.
32. Moore DE, Sithipitaks V. Photolytic degradation of furosemide. J Pharm Pharmacol 1983; 35: 489-493.
33. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma leveltime curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
34. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel-Dekker, 1982.
35. Choi YH, Lee MG. Effect of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D and 3A1/2 for the metabolism of metformin. Br J Pharmacol 2006: 149: 424-430.
36. Lee DY et al. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. Biopharm Drug Dispos 2006; 27: 209-218.
37. Inui S et al. Dose dependency of loop diuretics, furosemide and piretanide in the rat. Yakugaku Zasshi 1982; 102: 1053-1060.
38. Beermann B et al. On the fate of furosemide in man. Eur J Clin Pharmacol 1975; 9: 51-61.
39. Omiecinski CJ et al. Developmental expression and in situ localization of the phenobarbital-inducible rat hepatic mRNAs for cytochromes CYP2B1. CYP2B2, CYP2C6, and CYP3A1. Mol Pharmacol 1990: 38: 464-470.
40. Moon YJ et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003: 31: 776-784.
41. Kim YC et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1.3-dimethyluric acid formation. Eur J Pharm Sci 2005: 26; 114-123.
42. Cho MK et al. Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys 1999: 372: 150-158.
43. Chung HJ et al. Effects of E. coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites. M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11. J Pharm Sci 2008; 97: 5024-5036.
44. Yang KH et al. Time-dependent effects of Klebsiella pneumoniae endotoxin (KPLPS) on the pharmacokinetics of theophylline in rats: return of the parameters in 96-hour KPLPS rats to the control levels. Drug Metab Dispos 2008: 36: 811-815.
45. Choi HD et al. Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites. 1.3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats. Biopharm Drug Dispos 2007; 28: 445-454.
46. Kim EJ et al. Pharmacokinetics and pharmacodynamics of intravenous azosemide in mutant Nagase analbuminemic rats. Drug Metab Dispos 2003: 31: 194-201.